Ultrasmall Biocompatible Bi<sub>2</sub>Se<sub>3</sub> Nanodots for Multimodal Imaging-Guided Synergistic Radiophotothermal Therapy against Cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28024338.
- Also identified by DOI 10.1021/acsnano.6b06067.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sub-3 nm ultrasmall Bi<sub>2</sub>Se<sub>3</sub> nanodots stabilized with bovine serum albumin were successfully synthesized through a reaction of hydroxyethylthioselenide with bismuth chloride in aqueous solution under ambient conditions. These nanodots exhibit a high photothermal conversion efficiency (η = 50.7%) due to their strong broad absorbance in the near-infrared (NIR) window and serve as a nanotheranostic agent for photoacoustic imaging and photothermal cancer therapy. In addition, they also display radioenhancement with a ratio of 6% due to their sensitivity to X-rays, which makes them a potential sensitizer for radiotherapy. These nanodots were also labled with radioactive <sup>99m</sup>Tc for quantification of their biodistribution by single-photon-emission computed tomography (SPECT)/computed tomography (CT) imaging. Our work demonstrates the potential of ultrasmall Bi<sub>2</sub>Se<sub>3</sub> nanodots in multimodal imaging-guided synergetic radiophotothermal therapy of cancer.
Medical subject headings
- Organoselenium Compounds
- Theranostic Nanomedicine